NASDAQ : QTTB
Q32 Bio Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 8.71 USD (Nov 2, 2026, 4:00 PM EST) · Market cap 259.29M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 259.29M |
| Enterprise Value | 158.32M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 29.77M |
| Shares Outstanding | 29.77M |
| Shares Change (YoY) | +21.91% |
| Shares Change (QoQ) | +44.32% |
| Owned by Insiders (%) | 0.76% |
| Owned by Institutions (%) | 35.61% |
| Float | 12.72M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 3.83 |
| Forward PE | n/a |
| PS Ratio | 4.80 |
| Forward PS | 773.42 |
| PB Ratio | 2.00 |
| P/TBV Ratio | 2.43 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 4.64 |
| EV / Sales | 2.92 |
| EV / EBITDA | 7.19 |
| EV / EBIT | 7.31 |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 20.30 |
| Quick Ratio | 19.78 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 0.23 |
| Debt / FCF | n/a |
| Interest Coverage | 23.85 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 72.14% |
| Return on Assets (ROA) | 14.74% |
| Return on Invested Capital (ROIC) | 22.80% |
| Return on Capital Employed (ROCE) | 19.43% |
| Weighted Average Cost of Capital (WACC) | 3.85% |
| Revenue Per Employee | $2.44M |
| Profits Per Employee | $1.54M |
| Employee Count | 22 |
| Asset Turnover | 0.59 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.11 |
| 52-Week Price Change | +209.96% |
| 50-Day Moving Average | 10.30 |
| 200-Day Moving Average | 9.26 |
| Relative Strength Index (RSI) | 45.59 |
| Average Volume (20 Days) | 563,388 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5.65M |
| Short Previous Month | 4.67M |
| Short % of Shares Out | 18.99% |
| Short % of Float | 44.44% |
| Short Ratio (days to cover) | 5.24 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 53.74M |
| Gross Profit | 39.39M |
| Operating Income | 21.46M |
| Pretax Income | 33.79M |
| Net Income | 33.79M |
| EBITDA | 21.82M |
| EBIT | 21.46M |
| Earnings Per Share (EPS) | $2.27 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 106.27M |
| Total Debt | 5.30M |
| Net Cash | 100.97M |
| Net Cash Per Share | $3.39 |
| Equity (Book Value) | 105.91M |
| Book Value Per Share | 4.46 |
| Working Capital | 104.25M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -19.83M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 356,000 |
| Net Borrowing | -12.95M |
| Free Cash Flow | -19.83M |
| FCF Per Share | -$0.67 |
Margins
| Measure | Value |
|---|
| Gross Margin | 73.30% |
| Operating Margin | 39.94% |
| Pretax Margin | 62.87% |
| Profit Margin | 62.87% |
| EBITDA Margin | 40.60% |
| EBIT Margin | 39.94% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -21.91% |
| Shareholder Yield | -21.91% |
| Earnings Yield | 26.09% |
| FCF Yield | -7.69% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $39.67 |
| Price Target Difference | 355.45% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | -68.58% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 3.36 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |